28.10.2021 · Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the third quarter ended September 30, 2021.
1 dag siden · As previously disclosed, under the terms of the agreement, Blueprint Medicines acquired Lengo Therapeutics for $250 million in cash plus up to $215 million in additional potential payments based on...
The Investor Relations website contains information about Blueprint Medicines Corp.'s business for stockholders, potential investors, and financial ...
30.09.2021 · Blueprint Medicines will host a live conference call and webcast at 8:30 a.m. ET today to discuss third quarter 2021 financial results and recent business activities. The conference call may be accessed by dialing 844-200-6205 (domestic) or 929-526-1599 (international) and referring to conference ID 963004.
Apr 29, 2021 · Blueprint Medicines recorded revenues of $6.2 million in the first quarter of 2020, including $3.5 million of net product revenues from sales of AYVAKIT and $2.7 million in collaboration revenues ...
Sep 30, 2021 · Blueprint Medicines will host a live conference call and webcast at 8:30 a.m. ET today to discuss third quarter 2021 financial results and recent business activities. The conference call may be accessed by dialing 844-200-6205 (domestic) or 929-526-1599 (international) and referring to conference ID 963004.
Oct 29, 2020 · Blueprint Medicines recorded $9.1 million in collaboration revenues for the third quarter of 2019. Cost of Sales: Cost of sales was $0.1 million for the third quarter of 2020. Blueprint Medicines did not incur cost of sales in the third quarter of 2019, as no product sales were generated during that period.
29.04.2021 · Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the first quarter ended March 31, 2021.
Get the detailed quarterly/annual income statement for Blueprint Medicines Corporation (BPMC). Find out the revenue, expenses and profit or loss over the ...
Oct 28, 2021 · Blueprint Medicines Reports Third Quarter 2021 Financial Results. -- Strong AYVAKIT launch in advanced SM with $17.3 million in net product revenues in the first full quarter following U.S ...
Jul 29, 2021 · CAMBRIDGE, Mass., July 29, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the second quarter ended June 30,...
Funding Blueprint Medicines has raised a total of $1.1B in funding over 8 rounds. Their latest funding was raised on Mar 27, 2019 from a Post-IPO Equity round. Blueprint Medicines is registered under the ticker NASDAQ:BPMC . Their stock opened with $18.00 in its Apr 27, 2015 IPO. Blueprint Medicines is funded by 15 investors.
29.07.2021 · Blueprint recorded revenues of $8.3 million in the second quarter of 2020, including $5.7 million of net product revenues from sales of AYVAKIT and …